Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo aims to free hepatitis b patients from daily pills

NCT ID NCT04980482

Disease control Sponsor: Arbutus Biopharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tested an experimental drug called AB-729 combined with pegylated interferon and standard antiviral pills in 43 adults with chronic hepatitis B. The goal was to see if this approach could safely lower hepatitis B surface antigen levels and allow some participants to stop their daily antiviral therapy. The study is now complete, and results will show whether this combination can help control the virus long-term.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AB-729 (an experimental drug) and pegylated interferon alfa-2a
What this could lead to
If successful, this combination could help some people with chronic hepatitis B stop their daily antiviral pills and keep the virus under control.
What could go wrong
This is a small, early Phase 2 study with only 43 participants. It may not lead to lasting virus control, and side effects from the drugs could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

43 people

The number who actually took part.

Started

Oct 2021

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic hepatitis B virus infection with documentation at least 6 months prior to screening * Subjects must have been receiving either TAF, TDF (or equivalent), or ETV consistently for ≥12 months prior to dosing Day 1 * HBV DNA \<LLOQ at Screening * HBsAg between 100 and 5,000 IU/mL at Screening * Subjects must be HBeAg-negative at Screening * Fibroscan® result of ≤8.5 kPa within 6 months prior to dosing Day 1 * Medically stable based on physical examination, medical history, vital signs, laboratory values, and 12-lead Electrocardiogram (ECG) at screening Exclusion Criteria: * Evidence of co-infection with hepatitis A, C, D or E virus or human immunodeficiency virus (HIV) at screening * History of any clinically significant medical condition associated with chronic liver disease, cirrhosis, evidence of decompensated liver disease, or findings suggestive of hepatocellular carcinoma (HCC) at any time * Contraindications to the use of Peg-IFNα-2a or incapable of self-administration or assisted administration of Peg-IFNα-2a * Previous treatment with an experimental HBV-directed RNA-interference or antisense oligonucleotide product.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis B

Contacts and locations

Locations

  • Arensia Exploratory Medicine Moldova

    Chisinau, 2025, Moldova

  • Arizona Liver Health

    Chandler, Arizona, 85224, United States

  • Arizona Liver Health

    Tucson, Arizona, 85712, United States

  • Asan Medical Center

    Seoul, South Korea

  • Chia-Yi Christian Hospital

    Chiayi City, 60002, Taiwan

  • Chung-Ho Memorial Hospital

    Kaohsiung City, 83301, Taiwan

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • ID Care

    Hillsborough, New Jersey, 08844, United States

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, 83301, Taiwan

  • Medical Center of Limited Liability Company Harmoniya Krasy

    Kyiv, 01135, Ukraine

  • Nepean Hospital

    Kingswood, New South Wales, 2747, Australia

  • Prince of Wales Hospital, The Chinese University of Hong Kong

    Hong Kong, Hong Kong

  • Pusan National University Hospital

    Pusan, Republic of Korea, 49241, South Korea

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Research and Education, Inc.

    San Diego, California, 92105, United States

  • St Vincent's Hospital Melbourne

    Melbourne, Victoria, 3065, Australia

  • University of Miami Miller School of Medicine

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.